Compound ID | 3388
Class: Antibody (IgG1 mAb)
| Spectrum of activity: | Gram-positive |
| Details of activity: | Active against Staphylococcus aureus; binds and neutralizes Staphylococcus aureus alpha-toxin |
| Description: | Monoclonal antibody; reduces bacterial load and prolongs survival in infection models of bacteraemia and pneumoniae by Staphylococcus aureus |
| Institute where first reported: | Mabwell (Shanghai) Bioscience Co. |
| Year first mentioned: | 2021 |
| Highest developmental phase: | Phase 2 (NCTC04784312) |
| Development status: | Unknown |
| External links: | |
| Citation: | https://doi.org/10.1016/j.ijantimicag.2023.107075 |